WHYY released its semi-annual performance report, with a net profit attributable to the parent company of 44.68 million yuan, a year-on-year increase of 303.16%
WHYY released its 2025 semi-annual report, with revenue of 425 million yuan, a year-on-year increase of 7.64%; net profit attributable to shareholders of 44.68 million yuan, a year-on-year increase of 303.16%; net profit excluding non-recurring items of 42.74 million yuan, a year-on-year increase of 334.8%; basic earnings per share of 0.08 yuan. The company plans to distribute a cash dividend of 1.20 yuan for every 10 shares to all shareholders. Revenue from cardiovascular drugs was 294.2304 million yuan, a year-on-year increase of 11.53%
According to the Zhitong Finance APP, WHYY (002107.SZ) disclosed its semi-annual report for 2025, reporting revenue of 425 million yuan for the reporting period, a year-on-year increase of 7.64%; net profit attributable to shareholders of 44.68 million yuan, a year-on-year increase of 303.16%; net profit excluding non-recurring items of 42.74 million yuan, a year-on-year increase of 334.8%; basic earnings per share of 0.08 yuan. The company plans to distribute a cash dividend of 1.20 yuan (tax included) for every 10 shares to all shareholders.
Among the company's main product lines, revenue from cardiovascular and cerebrovascular system drugs was 294.23 million yuan, a year-on-year increase of 11.53%; revenue from musculoskeletal system drugs was 99.78 million yuan, a year-on-year increase of 3.72%; revenue from antiviral respiratory system drugs was 12.62 million yuan, a year-on-year increase of 9.02%; revenue from reproductive and urinary system drugs was 3.44 million yuan, a year-on-year increase of 4.68%
